Meta-Analysis: Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibody for Juvenile Idiopathic Arthritis

Table 1

Characteristics and test performance of the included studies of autoantibodies against cyclic citrullinated peptide.

First author, year (reference)	Location	Reference standard	Test	Assay manufacturer^#	Cutoff value	Mean or median age, y	Women %	Mean duration of illness, y	Case number	Control participants	Result
											TP	FP	FN	TN
Avčin, 2002 [13]	Italy	NA	CCP1	Euro-Diag-nostica	70 AU/mL	8.7	72.48	3.6	109	Healthy children ( = 30); SLE ( = 45)	2	2	107	73
Hromadnikova, 2002 [39]	Czech Republic	NA	CCP1	Euro-Diag-nostica	50 U/mL	16.5	54.29	1	140	Healthy children ( = 24)	7	0	133	24
Kasapçopur, 2004 [25]	Turkey	ILAR	CCP2	Euroimmun	40 IU/mL	8.8	59.0	4.3	122	Healthy children ( = 15); SLE ( = 19)	3	0	119	34
Low, 2004 [24]	United States	ACR	CCP2	Inova	NA	11.6	NA	12.4	66	Healthy controls ( = 25)	13	0	53	25
Ferucci, 2005 [6]	United States	ACR	CCP2	Axis-Shield	5 U/mL	14.69	73.91	9.66	230	Healthy children development of type 1 diabetes ( = 688)	13	4	217	684
Kwok, 2005 [22]	China	ILAR	CCP2	Inova	20 AU/mL	15.0	40.7	4.3	59	Other rheumatic diseases ( = 68); Healthy volunteers ( = 60)	6	2	53	126
Brunner, 2006 [26]	Austria	NA	CCP2	Euroimmun	5 U/mL	11.0	66.67	2.1	45	Healthy newborns; ( = 42); Other autoimmunopathies patients; ( = 38); Patients with other underlying diseases ( = 34)	2	9	43	105
Dewint, 2006 [30]	Belgium	ILAR	CCP2	Imunoscan	25 U/mL	10.5	78.3	1.3	44	Nonpolyarticular JIA ( = 38)	7	0	37	38
Gilliam, 2008 [20]	United States	ACR	CCP2	Inova	20 U/L	13.39	82.4	5.38	68	Healthy children ( = 18)	19	0	49	18
Habib, 2008 [28]	Egypt	ILAR	CCP2	Inova	20 U/mL	10.6	44.12	3.7	68	JSLE ( = 14); Healthy children ( = 20)	14	0	54	34
Lipińska, 2008 [31]	Poland	ILAR	CCP2	Euroimmun	5 RU/mL	NA	61.46	NA	96	Children with functional cardiovascular system dysfunction; ( = 22)	40	0	56	22
Kuna, 2009 [32]	Croatia	ILAR	CCP2	Euroimmun	5 RU/mL	11	73	3.4	56	Other juvenile rheumatic diseases; ( = 17)	1	0	55	17
Morbach, 2010 [33]	Germany	NA	CCP2	Human GmbH	NA	NA	NA	NA	191	Healthy children ( = 88)	5	1	186	87
Gilliam, 2011 [34]	United States	ACR	CCP3	Inova	20 U/mL	11.2	80.2	3.9	96	Pediatric-onset SLE ( = 19); Healthy children ( = 10)	14	0	82	29
Skare, 2011 [35]	Brazil	ILAR	CCP3	Inova	20 U/mL	25.3	73.4	15.31	49	Healthy volunteers ( = 100)	9	1	40	99
Tebo, 2012 [37]	United States	ILAR	CCP3	Inova	20 U/mL	6.5	65.5	NA	334	Healthy children ( = 50)	47	1	287	49
Gilliam, 2013 [38]	United States	NA	CCP3	Inova	20 U/mL	12	81.1	NA	95	SLE ( = 19); Healthy children ( = 10)	13	1	82	28

CCP = cyclic citrullinated peptide; SLE = systemic lupus erythematosus; ILAR = International League of Associations for Rheumatology; ACR = the American College of Rheumatology criteria; JSLE = juvenile systemic lupus erythematosus; JIA = juvenile idiopathic arthritis; TP = true-positive; FP = false-positive; FN = false-negative; TN = true-negative; NA = not available.
The generation of anti-CCP test in the following: methods section of the articles referenced. CCP3 refers to CCP3 from Inova and not CCP3.1.
The locations of the assay manufactures are as Euro-Diagnostica (Arnhem, Netherlands), Euroimmun (Luebeck, Germany), Inova (San Diego, California, USA), Axis-Shield (Dundee, United Kingdom), and Human GmbH (Mainz, Germany).